Cargando…

P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Shah, Nirav N, Fenske, Timothy, Johnson, Bryon, Szabo, Aniko, Devata, Sumana, Longo, Walter, Kearl, Tyce, Zamora, Anthony, Hari, Parameswaran, Schneider, Dina, Hamadani, Mehdi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430991/ http://dx.doi.org/10.1097/01.HS9.0000971224.20765.8e

Ejemplares similares

Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes
por: Knight, Jennifer M., et al.
Publicado: (2022)

Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy
por: Knight, Jennifer M., et al.
Publicado: (2022)

PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response
por: Zurko, Joanna, et al.
Publicado: (2021)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies
por: Ferl, Gregory Z., et al.
Publicado: (2018)

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone
por: Tuscano, Joseph M., et al.
Publicado: (2011)

P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY
por: Shah, Nirav, et al.
Publicado: (2023)

Surface Levels of CD20 Determine Anti-CD20 Antibodies Mediated Cell Death In Vitro
por: Singh, Vijay, et al.
Publicado: (2014)

Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma
por: Montraveta, Arnau, et al.
Publicado: (2014)

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19
por: Giovannoni, Gavin
Publicado: (2020)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
por: Liu, Yanlong, et al.
Publicado: (2022)

Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes
por: Hu, Changyun, et al.
Publicado: (2013)

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
por: Shinoda, Koji, et al.
Publicado: (2023)

Adriamycin‐loaded exosome with anti‐CD20 aptamers selectively suppresses human CD20+ melanoma stem cells
por: Chen, Hairong, et al.
Publicado: (2022)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

Should anti-CD20 be used as an immune reconstitution therapy?
por: Smets, Ide, et al.
Publicado: (2022)

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
por: Liu, Xinyuan, et al.
Publicado: (2023)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody
por: Li, Ziduo, et al.
Publicado: (2020)

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
por: Gui, Lin, et al.
Publicado: (2016)

Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response
por: Singh, Vijay, et al.
Publicado: (2015)

Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2019)

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
por: Baker, D., et al.
Publicado: (2020)

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Anti-CD20-Antikörpertherapie ist keine Kontraindikation für COVID-19-Impfung!
por: Wendtner, Clemens-Martin
Publicado: (2021)

Nucleocapsid Antigenemia in Patients Receiving Anti-CD20 Therapy With Protracted COVID-19
por: Wilber, Eli, et al.
Publicado: (2022)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
por: Florou, Despoina, et al.
Publicado: (2020)

Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab
por: Belviso, Benny Danilo, et al.
Publicado: (2022)

Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
por: Roach, Charles A., et al.
Publicado: (2021)

Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy
por: Heming, Michael, et al.
Publicado: (2023)

Fatale neurologische Nebenwirkung einer Anti-CD20-Antikörper-Therapie
por: Schmidt, Kathie, et al.
Publicado: (2022)

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
por: de Sèze, Jérôme, et al.
Publicado: (2023)

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity
por: Faber, Mary L., et al.
Publicado: (2023)

CD8(+) T Cell Immunity Is Compromised by Anti-CD20 Treatment and Rescued by Interleukin-17A
por: Fiocca Vernengo, Facundo, et al.
Publicado: (2020)

Anti-CD20 therapy depletes activated myelin-specific CD8(+) T cells in multiple sclerosis
por: Sabatino, Joseph J., et al.
Publicado: (2019)

Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy
por: Thakar, Monica S., et al.
Publicado: (2020)

Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists
por: Kant, Sam, et al.
Publicado: (2021)

Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy
por: Bazzi, Sam A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ckb9977m3ui97p2ehsf94er2r5